FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Poirier Michael S.		 2. Issuer Name and Ticker or Trading Symbol

Qualigen Therapeutics, Inc. [ QLGN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chairman, President & CEO.
(Last)          (First)          (Middle)

C/O QUALIGEN THERAPEUTICS, INC.,, 2042 CORTE DEL NOGAL		 3. Date of Earliest Transaction (MM/DD/YYYY)

5/22/2020
(Street)

CARLSBAD, CA 92011
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock (1)(2)5/22/2020  J(2)  169192 A (2)169192 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrant (Right to Buy) (3)$2.0663 5/22/2020  J   22142    5/22/2020 1/31/2024 Common Stock 22142  (3)22142 D  
Warrant (Right to Buy) (3)$2.0663 5/22/2020  J   29847    5/22/2020 8/2/2024 Common Stock 29847  (3)29847 D  
Warrant (Right to Buy) (3)$2.5405 5/22/2020  J   22142    5/22/2020 3/2/2025 Common Stock 22142  (3)22142 D  
Warrant (Right to Buy) (3)$2.5405 5/22/2020  J   14437    5/22/2020 9/22/2026 Common Stock 14437  (3)14437 D  
Explanation of Responses:
(1) On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer and director of the Issuer.
(2) Immediately prior to the Closing, the Reporting Person was a stockholder of Qualigen. Pursuant to the Merger, the shares of Qualigen common stock previously held by the Reporting Person were converted into 169,192 shares of common stock of the Issuer.
(3) Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Poirier Michael S.
C/O QUALIGEN THERAPEUTICS, INC.,
2042 CORTE DEL NOGAL
CARLSBAD, CA 92011		X
Chairman, President & CEO.
Signatures
/s/ Hayden Trubitt, Attorney-in-Fact for Michael S. Poirier5/27/2020
**Signature of Reporting PersonDate
Ritter Pharmaceuticals (NASDAQ:RTTR)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Ritter Pharmaceuticals.
Ritter Pharmaceuticals (NASDAQ:RTTR)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Ritter Pharmaceuticals.